

ANSWERING REVIEWERS

July 25, 2014

Dear Editor,



Please find enclosed the edited manuscript in Word format (file name: 12396-review.doc).

Title: FOLFIRI plus bevacizumab as a second line therapy for metastatic intrahepatic cholangiocarcinoma

Author: Jean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, Leila Bengrine, Francois Ghiringhelli

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 12396

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

Reviewer 1: 1. There are too many errors on the text about the trial. Some typing errors are as follow: At line 16 in page 3, standard of care for "unresectable" cholangiocarcinoma..... It would be unresectable. At line 21 in page 4, "inotecan" would be irinotecan. At line 8 in page 7,

We apologized for these mistakes and make the appropriate corrections

There are many abbreviations in this text that readers would be quite difficult to realize.

We replace the abbreviations by the complete term throughout the manuscript

The number of patients included in this phase 2 trial is very small and have to list limitation in discussion. Despite the regimen could provide a new treatment for 2nd line therapy in these subjects, the small number remains a limitation to make such a conclusion. Therefore, the authors may mention that a further larger scale prospective trial should be mandatory to confirm the conclusion!

As requested we add in the conclusion that "further larger scale prospective trial should be mandatory to confirm the conclusion"

Reviewer 2:

1. There are many clinical used abbreviations in this text that readers would be quite difficult to realize. I suggest authors could give a list to explain the abbreviations.

We replace the abbreviations by the complete term throughout the manuscript

2. Some typing errors are as follow: At line 16 in page 3, standard of care for "unresectable" cholangiocarcinoma..... It would be unresectable. At line 21 in page 4, "inotecan" would be irinotecan. At line 8 in page 7, At 2 "mo",... Is it "month"? 3. At line 20 in page 8, "A recent multicentric retrospective study in Italian" would replace "A recent multicentric retrospective Italian study". 4. At line 14 in page 3, the sentence "Recently, 2 phase III trials demonstrate that for oxaliplatin plus gemcitabine regimen[7]." is too long and needs to separate into 2 shorter sentences

We apologized for these mistakes and make the appropriate corrections

Reviewer 3:

1. The number of patients included in this phase 2 trial are very small

We agree with this point and underline this in the limitation of our study and add in the conclusion that "further larger scale prospective trial should be mandatory to confirm the conclusion"

- 1. By the inclusion criteria the patients should have (among others criteria) advanced BTC, refractory to gemcitabine-based first-line chemotherapy and received GC combination as second-line treatment. On the Results we verify that only 4 patients received intra-arterial gemcitabine/oxaliplatin although on Table 1 the authors refers 5 patients.**

We apologized for this mistake in the material and method part. We include in this study only patients that received gemcitabine plus oxaliplatin as a first line. We consider that intravenous or intraarterial injection of gemcitabine plus oxaliplatin are only one line of therapy. We make the appropriate correction in the text

- 2. In Abstract the authors underlined "a disease control rate of 77%" although on the results they say that "disease control rate was 84.5%".**

We apologized for this mistake in the abstract and make the appropriate correction

- 3. When authors say "propose off target usage of FOLFIRI bevacizumab" I think they should want to say "propose off label usage of FOLFIRI bevacizumab".**

We agree with this point and make the appropriate correction

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Professor François Ghiringhelli, MD, PhD
Head of TEAM 1 INSERM 866, "Chemotherapy, lipid metabolism and immune response"

Full Professor of Oncology, University of Burgundy,
Department of Medical Oncology
Center Georges Francois Leclerc
1 rue du professeur Marion 21000 Dijon, FRANCE